论文部分内容阅读
目的:观察血管内皮生子因子受体单抗和顺铂联合应用治疗荷Lewis瘤小鼠的疗效。方法:将32只C57BL小鼠分成4组(对照组、顺铂组、血管内皮生长因子受体单抗组、血管内皮生长因子受体单抗联合顺铂组),实验结束后分别处死荷Lewis瘤小鼠,测量肿瘤的长、短径,称取瘤重,计算肿瘤体积、抑瘤率,对有肺转移瘤的小鼠进行计数并作肿瘤的病理检查。结果:血管内皮生长因子受体单抗联合顺铂组有明显的抑瘤作用,抑瘤率为78.44％,明显高于顺铂组(40.01％)和血管肉皮生长因子受体单抗组(56.22％);血管内皮生长因子受体单抗联合顺铂组有肺转移瘤的鼠数为2只,明显少于顺铂组(6只)和血管内皮生长因子受体单抗组(5只)。结论:血管内皮生长因子受体单抗和顺铂有良好的协同抗肿瘤作用,可提高疗效,为临床应用提供了科学依据。
OBJECTIVE: To observe the efficacy of vascular endothelial growth factor receptor monoclonal antibody and cisplatin in the treatment of Lewis-bearing mice. METHODS: Thirty-two C57BL mice were divided into 4 groups (control group, cisplatin group, vascular endothelial growth factor receptor monoclonal antibody group, vascular endothelial growth factor receptor monoclonal antibody, and cisplatin group), and Lewis mice were sacrificed at the end of the experiment. In tumor mice, the length and diameter of the tumor were measured, and the tumor weight was weighed. The tumor volume and tumor inhibition rate were calculated. The mice with pulmonary metastases were counted and pathologically examined for tumors. RESULTS: The anti-tumor effect of vascular endothelial growth factor receptor monoclonal antibody combined with cisplatin group was obvious, and the tumor inhibition rate was 78.44%, which was significantly higher than that of cisplatin group (40.01%) and vascular dermal growth factor receptor monoclonal antibody group (56.22%). There were 2 lung metastatic tumors in the vascular endothelial growth factor receptor monoclonal antibody plus cisplatin group, which was significantly less than the cisplatin group (6) and the vascular endothelial growth factor receptor monoclonal antibody (5). Conclusion: The vascular endothelial growth factor receptor monoclonal antibody and cisplatin have a good synergistic anti-tumor effect, which can improve the therapeutic effect and provide scientific basis for clinical application.